Leadership

Tony J. Hunt was named President and CEO and has served on the Board since May 2015. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations. Before coming to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt also serves on the board of directors of one publicly traded company, 908 Devices Inc. Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management. Mr. Hunt brings to the Board his deep understanding of the bioprocessing market.

Olivier Loeillot joined Repligen in October 2023 as President and Chief Commercial Officer (CCO), where he has responsibility for driving the company’s commercial strategy and expanding the market impact of Repligen’s business units in bioprocessing. Mr. Loeillot joined Repligen from his most recent role as Chief Executive Officer (CEO) of Ascensus Specialties, a manufacturer of specialty chemicals for use in the life sciences and pharmaceutical markets. Mr Loeillot previously served a combined 12 years with Cytiva (a Danaher company) and GE Healthcare Life Sciences. At Cytiva, he served as Bioprocess President from 2018 to 2022, overseeing the overall Bioprocess portfolio from cell culture media to purification resins and including process equipment, single-use technologies and enterprise solutions. There, he was also instrumental in building and leading the Enterprise Solutions business, managing the Bioprocess ASIA business in Singapore, and directing the Genomics and Cellular Research division. Prior to Cytiva, Mr. Loeillot served a combined 12 years with Lonza, advancing to Vice President Sales, Lonza Custom Manufacturing. He also acted as Vice President of Sales for Lonza AG’s Custom Manufacturing Business and led the Microbial Biopharmaceuticals group. Mr. Loeillot earned his Master’s degree in Chemistry in 1993 from the European High Institute of Chemistry (EHICS) of Strasbourg, France, and later completed a Master’s of Business Administration (MBA) program at CESMA Business School of EM Lyon.

Jason K. Garland joined Repligen in September 2023 as Chief Financial Officer (CFO), where he oversees financial operations for the company. He holds responsibility for all corporate finance and audit functions, capital markets and M&A transactions, financial planning and analysis, budgeting and risk management. Mr. Garland was previously with Integer Holdings Corporation, a medical device outsource (MDO) manufacturer, where he served for nearly five years as Executive Vice President and CFO, and assumed executive sponsorship of the company’s Business Process Excellence initiative focused on standardizing and optimizing all non-manufacturing processes. Prior to his role with Integer, Mr. Garland spent three years as Vice President and CFO for the global sales and supply divisions of Tiffany & Co., following nearly 20 years in various roles of increasing responsibility at GE. His rotations and achievements at GE culminated in several leadership positions including his role as CFO for GE Industrial Solutions; then a multi-billion dollar business with over 40 manufacturing sites. Mr. Garland serves on the Board and is Audit Chair for Acutus Medical, a publicly traded medical device company. He holds a B.S. in Chemical Engineering from the University of New Hampshire, and is Lean Six Sigma Black Belt certified.

James R. Bylund was named Chief Operating Officer of the Company in January 2022 and serves as the Company’s principal operating officer. He joined Repligen in March of 2020 as Senior Vice President, Global Operations and IT, overseeing all operations and IT functions on a global basis. Between March 2019 and March 2020, Mr. Bylund also worked in real estate at Inspire Development in Austin, Texas. Prior to joining Repligen, Mr. Bylund spent ten years at Thermo Fisher Scientific in a number of roles including Vice President and General Manager of the Single Use Technologies Business Unit and Vice President of Global Operations for the Bioproduction Division. Prior to joining Thermo Fisher, Mr. Bylund also worked for Fiserv (9 years) and Eli Lilly and Company (7 years) in a variety of leadership roles. He has significant experience in managing multiple operating sites across the globe and scaling operations to meet rapidly growing demand. Mr. Bylund is a passionate proponent of continuous improvement and has consistently demonstrated the ability to assemble and grow highly effective teams. He holds a B.S. in Accounting from Utah State University and an M.B.A. from Indiana University.

Christine Gebski joined Repligen in May 2015 and currently serves as the Senior Vice President, Filtration and Chromatography where she oversees the general management and strategy of the Company’s upstream and downstream filtration and chromatography portfolio. Ms. Gebski also manages the Field Applications function within the Company, ensuring strong customer experience. Prior to joining Repligen, Ms. Gebski was head of the Chromatography Business Unit within the Bioproduction Division of Thermo Fisher Scientific. At Thermo Fisher she managed the Global Process Chromatography Applications and R&D functions for ten years. Before joining Thermo Fisher Scientific, Ms. Gebski was a Process Development Scientist for 15 years in the biotechnology industry, having held positions of increasing responsibility at Genzyme, TKT/Shire and EMD Pharmaceuticals. She has significant experience in downstream process development and engineering, technology transfer and validation across a variety of biological molecule classes and diagnostic reagents. She holds a B.S. in Biology from the University of Vermont and a M.S. in Biotechnology from the University of Massachusetts at Lowell.

Ralf Kuriyel joined Repligen in October 2016 as the Senior Vice President, Research and Development where he oversees the Company’s R&D efforts. Mr. Kuriyel was previously Vice President of Applications for the singleuse business unit within the Life Sciences division of Pall Corporation (“Pall”), whose acquisition by Danaher Corporation was completed in August 2015. At Pall, Mr. Kuriyel served as Vice President of R&D, Field Applications and Process Development Services from November 2014 to October 2016. In addition, Mr. Kuriyel served as Vice President, Applications R&D at Pall from November 2011 to November 2014. Mr. Kuriyel received a B.S. and an M.S. in Chemical Engineering from Rensselaer Polytechnic Institute and has completed his coursework for the Tufts University Ph.D. program in Chemical Engineering. He is an inventor of multiple patents and has co-authored over 30 scientific publications on bioprocessing, including separations technologies, membrane separations methods, protein processing and enhanced microfiltration techniques.

Gautam Choudhary joined Repligen in November 2018 as Vice President and General Manager of Bioprocess Systems and Automation. He is responsible for building the infrastructure and developing the strategy for TFF systems and advancing workflows for continuous manufacturing. Before coming to Repligen, Gautam worked at Lonza supporting strategic and operational projects and developing the go-to-market strategy for Cell and Gene Therapy for Bioscience Solutions.  Prior to Lonza, he spent twelve years at Life Technologies/Thermo Fisher leading the Cell Culture (Gibco) business for Bioproduction.  Before joining Life, he held several technical and commercial roles at Millipore in Asia and Europe supporting filtration, chromatography and the systems business.  Mr. Choudhary holds a Bachelor's Degree in Mechanical Engineering and an MBA in Marketing from Leeds University, UK.

General Counsel

Leslie joined Repligen in May 2022, initially leading the US and European HR teams supporting the COO global organization. In September 2022, she moved into the Global Head, Human Resources role where she is responsible for leading Repligen’s overall human resources function including strategy, global talent acquisition, employee development, diversity & inclusion, and HR operations. Leslie has over twenty years of global HR leadership experience in the life sciences, healthcare, and high-tech manufacturing industries. Leslie earned her bachelor’s degree in Human Resources and Industrial and Labor Relations from Bowling Green State University, her M.S.A. in Human Resources from Central Michigan University and her J.D. with a concentration in Employment Law from Capital University.   

Dr. Jaime M. Humara joined Repligen in November 2022 and currently serves as the Senior Vice President of Global Marketing, overseeing the corporate, digital and strategic marketing functions for the organization. Prior to joining Repligen, Dr. Humara spent 3.5 years as Vice President of Worldwide Marketing for the Biosciences unit of Beckton Dickinson. During his tenure, he built the downstream strategic marketing function for the business unit and hired and led a team of 28 marketing professionals with responsibilities for web and eCommerce, global demand generation campaigns, scientific marketing, and analytics for the entire $1.4B portfolio of research and clinical solutions for immunology, reporting to both the President of BD Biosciences and the Chief Marketing Officer of BD.

Prior to joining BD, Dr. Humara was the Vice President of Global Marketing for the Life Science Group at Bio-Rad, where he led a team of marketing professionals with global responsibilities for upstream, downstream, and marketing communications and brand for key businesses that hold leadership positions in protein quantification and imaging, protein purification, gene expression and cell biology.

Before, he served as the Director of Global Strategic Marketing for Beckman Coulter Diagnostics and led a multi-regional team responsible for the global launch of a new CE-mark molecular diagnostics platform and assay portfolio, as well as being instrumental to Danaher’s acquisition of Cepheid.

Dr. Humara started his marketing career in the early 2000’s at Thermo Fisher Scientific (formerly Life Technologies), where he held multiple global and regional marketing roles, M&A, and integration during his 9 years with the firm.

Dr. Humara earned his doctorate in Plant Biotechnology in 1994, and has a BS in Biological Sciences, both from the University of Oviedo, Spain.

Kola Otitoju joined Repligen in 2020 as Senior Vice President of Strategy and Business Development. He is responsible for leading the development and execution of the Repligen growth strategy including partnerships, licensing, investments and mergers and acquisitions. Mr. Otitoju brings a wealth of experience in strategic planning and execution having led multiple transactions in excess of $100BN through his tenures in Investment Banking M&A at Credit Suisse and Banc of America Securities (8 years), large publicly traded corporations including Baxter and GE Healthcare (6 years), and private equity-backed companies like Candela Medical with Apax Partners (3 years). He also brings a strong technical background having been an Electrical Engineer earlier in his career. Mr. Otitoju has Masters Degrees in Business Administration from Harvard Business School and Electrical Engineering from Cornell University, in addition to a Bachelor's Degree in Information Systems Engineering from Imperial College London.

A Jamaican native, Keith has over 2 decades of experience consulting on and managing information systems and information technology in multiple industries in the United States, Canada and the Caribbean. He has been employed at Repligen since 2015 in different IT leadership roles, building and leading a global IT organization. As Chief Information Officer, Keith’s main priorities are to enable and optimize business productivity, drive technological innovation, protect the company’s digital assets and to run an efficient IT organization Keith earned a Master’s of Science degree in Management Information Systems from the University of the West Indies, Jamaica.

Mark Salerno joined Repligen as part of the C Technologies, Inc. acquisition in 2019 and currently serves as Vice President and Global Head of the Process Analytics business unit. Mr. Salerno brings over twenty-five years of experience to Repligen, where he is responsible for R&D, Operations, Quality and Commercial activities leading the team that is working to expanding the PAT portfolio to bring disruptive and enabling technologies to the bio-pharmaceutical industry.  Mr. Salerno is an inventor of numerous patents on fiber optic solutions and instrumentation, most notably the CTech™ SoloVPE®, CTech™ FlowVPX® and variable pathlength technologies.   He holds a bachelor’s degree in mechanical engineering from the University of Notre Dame and an MBA in from the Seton Hall University Stillman School of Business. 

A graduate from the University of Leeds, England, Stephen Tingley has been a recognized contributor to the bioprocessing industry for over 25 years. Having worked initially for GSK, Mr. Tingley then joined Millipore creating and sharing expertise in sterile and downstream processing. At Millipore, Mr. Tingley became a recognized early champion of the development and adoption of single use technologies. He has had experience commercializing several leading technologies, including massively parallel microbioreactors system for upstream process development, multi-column chromatography and, most recently, leading the disposable chromatography team at Repligen that developed the OPUS^® pre-packed column line.

Greg Titus joined Repligen in March 2023 and currently serves as Senior Vice President Commercial Development. Mr. Titus is responsible for developing and implementing Repligen corporate commercial strategy, as well as developing and leading top-down sales initiatives across the global commercial organization. He brings over 30 years of life sciences industry experience to Repligen, including development and leadership of bioprocessing commercial strategies and teams within the US and globally. Prior to joining Repligen, Mr. Titus spent a combined 13 years with Cytiva (a Danaher company and previously GE Healthcare Life Sciences), including his most recent role was as General Manager, Global Strategic Accounts and Advanced Therapies. He also spent 17 years at EMD Millipore (now Millipore Sigma), leading Key Account Management programs and Business Development. Mr. Titus began his career in various service engineering, technical specialist and sales roles that lead to more strategic and operational opportunities. Greg has a degree in Electrical & Computer Engineering from Heald Institute of Technology and specialty certificates from Harvard Business “Advanced Negotiations” and El Camino College Los Angeles “The Art of Negotiations”.  He grew-up and currently lives in Napa Valley California, and is the founder & winemaker of Ominous Cellars.

Neil Whitfield joined Repligen in May 2020 as Vice President, Commercial Development and in October 2022 took the role of Vice President, Global Sales. Mr. Whitfield is responsible for building and developing a world class sales organization that executes effectively and delivers a positive customer experience. Before joining Repligen, Neil worked at Thermo Fisher Scientific Inc. where he led the commercial organization for the Bioproduction Division in EMEA for 9 years and successfully integrated the commercial organizations of Life Technologies and Thermo Fisher Scientific into one cohesive team. Prior to that, Mr. Whitfield spent 25 years at Applied Biosystems in various operational roles, before moving into the commercial organization to lead the Applied Markets Division in Europe and Middle East for Process Analytics, Food Pathogens and Animal Diagnostics. Mr. Whitfield holds a Higher National qualification in Chemistry from the University of Manchester, U.K. and a Post Graduate Diploma in Business Management from Liverpool University, U.K.